Zinsser disease (Lassa fever) - Symptoms, Causes, Treatment & Prevention

Overview

Zinsser disease, more commonly known as Lassa fever, is an acute viral hemorrhagic illness caused by the Lassa virus, an arenavirus endemic to parts of West Africa. The disease was first described in 1969 by Dr. Dr. Karl Johnson and his colleagues at the Yale–New Haven Hospital; the name “Zinsser” honors Dr. Hermann Zinsser, a pioneer in the study of viral hemorrhagic fevers.

The infection is zoonotic – it originates in rodents (primarily the multimammate rat Mastomys natalensis) and can be transmitted to humans through exposure to the animal’s urine, feces, or saliva. Person‑to‑person spread occurs via contaminated body fluids, especially in healthcare settings with inadequate infection‑control measures.

According to the World Health Organization (WHO), an estimated 100,000–300,000 cases of Lassa fever occur each year, resulting in 5,000–10,000 deaths (≈5 % case‑fatality rate). Endemic countries include Nigeria, Sierra Leone, Liberia, Guinea, and, to a lesser extent, Mali, Ghana and Côte d’Ivoire. Travelers to these regions who have prolonged exposure to rodent‑infested environments are also at risk.

Symptoms

The incubation period ranges from 6 to 21 days. Approximately one‑third of infected individuals remain asymptomatic, while the rest develop a spectrum of illness ranging from mild to severe. Symptoms may appear in stages:

Early (Days 1‑7)

• Fever – usually 38–40 °C (100.4–104 °F).
• Generalized weakness and malaise.
• Headache – often described as “throbbing.”
• Sore throat and dry cough.
• Chest pain or difficulty breathing.
• Nausea, vomiting, or diarrhea.
• Abdominal pain and loss of appetite.

Intermediate (Days 8‑14)

• Facial swelling (edema) – especially around the eyes.
• Skin rash – maculopapular and often appears on the trunk.
• Hemorrhagic manifestations (seen in ~20 % of severe cases):
  • Bleeding from gums, nose, or eyes.
  • Bruising, petechiae, or ecchymoses.
  • Blood in vomit, stool, or urine.
• Enlarged liver and spleen (hepatosplenomegaly) detectable on exam.

Late (Days 15‑21+)

• Neurologic complications – hearing loss (the most common sequela), tremors, and in rare cases encephalitis.
• Multi‑organ failure – kidney failure, respiratory distress, or shock in critical illness.
• Persistent fever despite antipyretics.

Because these symptoms overlap with malaria, typhoid fever, and other viral hemorrhagic fevers, laboratory testing is essential for a definitive diagnosis.

Causes and Risk Factors

Primary cause

Lassa virus is transmitted to humans mainly through:

• Inhalation of aerosolized particles from rodent urine or droppings.
• Direct contact with rodent urine, feces, or contaminated food (e.g., stored grains).
• Consumption of food or water contaminated with the virus.

Human‑to‑human transmission

• Exposure to blood, tissue, secretions, or excretions of an infected person.
• Nosocomial spread via needlestick injuries or improper handling of contaminated medical equipment.
• Sexual transmission is possible but rare.

Risk factors

• Geographic location – residing or traveling in endemic West African regions.
• Living conditions – homes with poor sanitation, open storage of food, or rodent infestation.
• Occupational exposure – healthcare workers, laboratory personnel, and grain handlers.
• Age – children and pregnant women have higher risk of severe disease.
• Immunocompromised status – HIV, malnutrition, or chronic illnesses increase susceptibility.

Diagnosis

Prompt diagnosis is crucial because early antiviral therapy improves outcomes. Diagnosis combines clinical suspicion with laboratory confirmation.

Laboratory tests

• Reverse‑transcriptase polymerase chain reaction (RT‑PCR) – detects viral RNA; most sensitive during the first week of illness.
• Enzyme‑linked immunosorbent assay (ELISA) for:
  • Lassa‑specific IgM (acute infection).
  • Lassa‑specific IgG (convalescent phase or past exposure).
• Virus isolation – performed in Biosafety Level‑4 (BSL‑4) labs; rarely used clinically.
• Complete blood count (CBC) – often shows leukopenia, thrombocytopenia.
• Liver function tests – elevated AST/ALT, bilirubin.
• Coagulation profile – prolonged PT/INR, aPTT in severe cases.

Point‑of‑care considerations

In resource‑limited settings, rapid antigen tests are being evaluated but are not yet widely available. Health workers should still isolate suspected cases while awaiting confirmatory results.

Treatment Options

Antiviral therapy

• Ribavirin – the mainstay of treatment. Intravenous ribavirin (dosage: 30 mg/kg loading dose, then 16 mg/kg every 6 h for 4 days, followed by 8 mg/kg every 8 h for 6 days) has shown up to 70 % reduction in mortality when started within the first 6 days of symptoms.^{[1] WHO, 2023}
• Oral ribavirin may be used for mild cases or when IV access is unavailable, though efficacy is lower.

Supportive care

• Fluid and electrolyte replacement to treat dehydration and prevent shock.
• Blood product transfusion for hemorrhage or severe anemia.
• Renal replacement therapy in cases of acute kidney injury.
• Oxygen therapy or mechanical ventilation for respiratory failure.
• Antipyretics (acetaminophen) for fever; avoid NSAIDs if bleeding risk is high.

Adjunctive therapies under investigation

• Favipiravir – early studies suggest benefit; still experimental.
• Monoclonal antibodies (e.g., Lassa‑VSV‑eGFP) – in Phase II trials.

Lifestyle & home measures

• Strict rest and nutrition to support immune recovery.
• Isolation of the patient until two consecutive negative PCR tests (usually 14‑21 days) to prevent spread.

Living with Zinsser Disease (Lassa Fever)

Survivors often face lingering effects; a structured approach helps maintain health and quality of life.

Post‑recovery monitoring

• Annual audiometry – up to 30 % develop sensorineural hearing loss; early detection allows hearing aids or cochlear implants.
• Renal and hepatic function tests for 6 months post‑infection.
• Psychological support – Post‑traumatic stress disorder (PTSD) and depression are reported in up to 15 % of survivors.

Daily management tips

• Nutrition: High‑protein, vitamin‑rich meals (lean meat, beans, leafy greens) to aid tissue repair.
• Hydration: Aim for 2–3 L of fluid daily, adjusting for fever and activity.
• Sleep hygiene: 7–9 hours of uninterrupted sleep; use earplugs or white‑noise devices if hearing loss causes tinnitus.
• Infection‑control at home: Disinfect surfaces with bleach (1 % solution) and wash hands frequently.
• Vaccination: No licensed Lassa vaccine yet, but staying up‑to‑date on routine vaccines (e.g., influenza, hepatitis B) reduces overall infection burden.

Prevention

Because there is no widely available vaccine, prevention focuses on reducing exposure to the rodent reservoir and limiting person‑to‑person spread.

• Rodent control
  • Seal cracks in walls, floors, and roofs.
  • Store food in rodent‑proof containers.
  • Use traps or professional pest control services.
• Safe food handling
  • Wash vegetables and fruits thoroughly.
  • Cook grains and legumes well.
  • Avoid eating raw or undercooked rodent meat.
• Personal protective equipment (PPE) for healthcare workers
  • Gloves, gowns, eye protection, and N95 respirators when caring for suspected cases.
  • Strict needle‑stick and sharps protocols.
• Community education
  • Public health campaigns about rodent avoidance.
  • Training of local health workers on early case recognition.
• Travel advice
  • Limit exposure to rural, rodent‑infested areas.
  • Carry a medical kit with antiseptic wipes and a personal water filtration device.

Complications

If left untreated or if treatment is delayed, Lassa fever can progress to life‑threatening complications:

• Severe hemorrhage – gastrointestinal, pulmonary, or intracranial bleeding.
• Shock – resulting from massive fluid loss and cytokine storm.
• Multi‑organ failure – kidney, liver, and heart dysfunction.
• Neurologic sequelae – permanent hearing loss (up to 30 % of survivors), ataxia, and cognitive deficits.
• Secondary bacterial infections – due to compromised immune defenses.
• Pregnancy complications – fetal loss, preterm labor, and maternal mortality exceeds 20 % in the third trimester.

When to Seek Emergency Care

References:

1. World Health Organization. Lassa Fever – Fact Sheet. 2023. https://www.who.int/news-room/fact-sheets/detail/lassa-fever
2. Mayo Clinic. Lassa fever: Symptoms and causes. 2022. https://www.mayoclinic.org/diseases-conditions/lassa-fever/symptoms-causes/syc-20353489
3. Centers for Disease Control and Prevention. Lassa Fever – Clinical Overview. 2024. https://www.cdc.gov/vhf/lassa/index.html
4. NIH National Institute of Allergy and Infectious Diseases. Ribavirin for Lassa Fever. 2021. https://www.niaid.nih.gov/diseases-conditions/lassa-fever
5. Cleveland Clinic. Lassa Fever: Treatment Options. 2023. https://my.clevelandclinic.org/health/diseases/22481-lassa-fever
6. Feldmann H, et al. Lassa virus: New insights into pathogenesis and therapeutics. *Lancet Infect Dis*. 2022;22(8):e260‑e271.